Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms:
WGYRGFYC
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | WGYRGFYC (WC8) is a peptide that selectively targets HER2 by mimicking the antigen-binding site of trastuzumab to bind specifically to HER2. Its DOTA precursor exhibits a dissociation constant (KD) of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, monitoring dynamic downregulation of HER2 expression. The compound rapidly distributes to target tissues and is efficiently cleared from non-target tissues through the kidneys, offering an optimal tumor-to-background ratio for imaging. It is a component of the PET radiotracer Ga-DOTA-WC8 and shows no significant cytotoxicity in breast cancer cells, making it suitable for non-invasive imaging diagnosis and treatment evaluation of HER2-positive breast cancer [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.